OpportunityAnalyzer:尋常痤瘡 - 機會分析與預測
OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
|出版日期||內容資訊||英文 177 Pages
|OpportunityAnalyzer:尋常痤瘡 - 機會分析與預測 OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018|
|出版日期: 2014年06月20日||內容資訊: 英文 177 Pages||
Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options for acne, though with the exception of isotretinoin, most only provide symptomatic relief as opposed to a curative or disease-modifying solution. However, isotretinoin is unable to serve a significant proportion of the acne market owed to its teratogenic nature, making its prescription for women of child-bearing age problematic.
In the past decade, there has been a shift in the acne market, with greater appreciation of its patient pool and potential for a lucrative payoff. Furthermore, there has been greater stress put on the social and psychological implications of the disease, which impact patients' quality of life. As a result, R&D investments have been initiated by key pharmaceutical players.
Key strategies underway in the acne market include -